FDA warned iwi that its iwi Cholesterol supplement is an unapproved new drug because website claims say it lowers cholesterol.
What happened
FDA reviewed iwi's website in October 2022, along with Facebook, Amazon and Walmart pages that direct consumers to buy iwi Cholesterol. FDA found claims such as “clinically shown to decrease cholesterol” and “lowering bad cholesterol,” which show the supplement is intended to treat or prevent disease. FDA says the product is therefore an unapproved new drug and is misbranded because it lacks adequate directions for use.
What FDA found
The website, Facebook, Amazon and Walmart claims show iwi Cholesterol is intended to treat or prevent disease, so FDA treats it as a drug.
section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]The product is an unapproved new drug because it is not generally recognized as safe and effective for the claimed cholesterol and heart uses and has no FDA approval.
section 201(p) of the Act [21 U.S.C. 321(p)]; sections 301(d) and 505(a) [21 U.S.C. 331(d), 355(a)]The product is misbranded because it lacks adequate directions for a layperson to use it safely for its intended purposes.
section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5Selling the misbranded drug in interstate commerce violates the Act.
section 301(a) of the Act [21 U.S.C. 331(a)]
What FDA wants
Within 15 working days of receipt, notify FDA in writing of the specific steps taken to address the violations, including steps to prevent recurrence and copies of related documentation. If correction cannot be completed in that time, state the reason and when it will be completed; if iwi believes the product is not in violation, include its reasoning and supporting information.
Who should pay attention
- Dietary supplement brands making cholesterol or heart-health claims
- Retailers and online marketplaces selling supplement listings
- Marketing and regulatory teams reviewing disease claims
This is a summary. Read the original letter on fda.gov.